Targeting BAFF and APRIL in MG

This episode, titled ‘Targeting BAFF and APRIL in MG,’ features panelists examining the biology and emerging clinical evidence surrounding dual BAFF/APRIL inhibition. The experts explain that BAFF and APRIL are soluble survival signals that interact with receptors on B cells and support maturation, differentiation, survival, and immune function. By binding these factors before they reach their receptors, dual-pathway inhibition can reduce the survival support available to B-cell and plasma-cell populations.

The panel discusses clinical findings with telitacicept, including phase 3 and longer-term data generated in China. Faculty highlight the depth and continued progression of clinical improvement observed over follow-up, while also noting the unusually low placebo response in the initial study. The experts discuss the need to understand whether geographic, cultural, patient-reporting, or population differences contributed to that observation and express interest in whether global study results reproduce the magnitude and durability of benefit.

Safety is another focus. Panelists consider changes in circulating immunoglobulin levels and how the immune effects of BAFF/APRIL inhibition may differ from those of direct B-cell depletion.

The discussion also places this mechanism within the broader treatment landscape. FcRn and complement inhibitors may demonstrate separation from placebo relatively quickly, whereas B-cell depletion generally develops more gradually. Based on available trial data, dual BAFF/APRIL inhibition appears to have an intermediate onset. The panel concludes by identifying depth of response, durability, placebo behavior, and sustained safety as important questions for ongoing global investigation.

In the next episode, ‘Addressing Unmet Needs with Emerging MG Therapies,’ panelists will evaluate future approaches including combination strategies, cellular therapy, antigen-specific tolerance, and the potential for more durable immune control.